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Thrombospondin 1 precedes and predicts the development of tubulo-
interstitial fibrosis in glomerular disease in the rat. Tubulointerstitial
fibrosis is one of the most important histologic features that predicts
progression in kidney disease. Thrombospondin 1 is an extracellular
matrix protein that can activate latent TGF-b, a cytokine implicated in the
pathogenesis of tubulointerstitial fibrosis. We examined the expression of
thrombospondin 1 in several animal models of glomerulonephritis (anti-
Thy1 model, aminonucleoside nephrosis, passive Heymann nephritis) that
are associated with tubulointerstitial disease. Thrombospondin 1 mRNA
and protein were transiently increased in tubular cells, myofibroblasts and
some macrophages in areas of tubulointerstitial injury. Thrombospondin 1
expression always preceded the development of tubulointerstitial fibrosis,
and correlated quantitatively and spatially with the later development of
interstitial fibrosis. Thrombospondin 1 expression predicted the severity of
tubulointerstitial fibrosis better than the degree of macrophage or myofi-
broblast accumulation. Thrombospondin 1 expression was associated with
increased expression and activation of TGF-b1 and decreased expression
of LAP-TGF-b in areas of tubulointerstitial injury. We conclude that
thrombospondin 1 is an early marker predicting the development of
tubulointerstitial kidney disease. De novo expression of thrombospondin 1
is associated and colocalized with increased expression of TGF-b1 and
decreased expression of LAP-TGF-b during the development of tubulo-
interstitial disease in vivo. These data are consistent with the possibility
that thrombospondin 1 may be an endogenous activator of TGF-b.
Tubulointerstitial inflammation and fibrosis are common in
most human glomerular diseases and have been found to predict
the risk for progression [1–4]. However, the pathogenic mecha-
nisms causing the interstitial injury are poorly understood. Recent
studies have implicated infiltrating macrophages [5, 6], myofibro-
blasts [7–9], and cytokines such as platelet-derived growth factor
BB (PDGF-BB) [10, 11] and transforming growth factor-beta
(TGF-b) [12] with the development of tubulointerstitial fibrosis.
Thrombospondin 1 (TSP1) is an extracellular, PDGF and basic
fibroblast growth factor (bFGF) inducible protein that has been
implicated in fibroblast, smooth muscle cell, and mesangial cell
(MC) proliferation and migration [13–15]. In addition, TSP1 has
also been shown to activate transforming TGF-b from its latent
form by a non-proteolytic mechanism [16, 17]. TGF-b has been
linked to matrix expansion in both glomerular and tubulointersti-
tial disease [12, 18], but the mechanism of TGF-b activation in
vivo in renal disease remains unknown.
We therefore decided to examine the expression of TSP1 in
several experimental models of glomerular disease in which
tubulointerstitial injury occurs, to determine if the expression
correlated with the development of fibrosis.
METHODS
Experimental design
Three models of acute glomerulonephritis were selected in
which tubulointerstitial injury and fibrosis develops: (1) anti-Thy1
model, a model of mesangial proliferative nephritis induced by an
antibody to the Thy1 antigen on MC; (2) aminonucleoside
nephrosis (PAN), a model of minimal change disease induced by
a single i.v. injection of puromycin; and (3) passive Heyman
nephritis (PHN), a model of membranous nephropathy induced
by a single i.p. injection of sheep anti-Fx1A antibody.
At various time points (from 2 days to 21 days) after disease
induction renal biopsies (N 5 6 to 9 per model and time point)
were obtained, immunostained and graded for interstitial TSP1
expression, myofibroblast formation (a-smooth muscle actin),
macrophage accumulation (ED-1) and proliferation (PCNA-pro-
liferating cell nuclear antigen). The specific cell types expressing
TSP1 in normal and diseased states were identified by double
labeling of TSP1 with cell specific markers for myofibroblasts
(a-smooth muscle actin), and macrophages (ED-1). To determine
if sites of TSP1 expression co-localize with cytokines such as
PDGF and TGF-b1 double labeling of TSP1 with antibodies to
PDGF-BB, TGF-b1 and the latency associated peptide of TGF-b
(LAP-TGF-b1) was performed. The tubulointerstitial expression
of TSP1 mRNA was studied by in situ hybridization using a
specific 35S-labeled cRNA probe. Immunostaining for a-smooth
muscle actin was combined with in situ hybridization for TSP1
mRNA to identify the cell types expressing TSP1 mRNA.
To determine whether TSP1 expression is associated with
increased expression and possibly activation of TGF-b1 the
bioactivity of TGF-b1 in cortical tissue samples obtained at day 11
was correlated with the degree of tubulointerstitial TSP1 immu-
nostaining in biopsies from individual control, PAN and PHN
animals obtained at the same time (N 5 4 to 5). Additionally,
double staining for TSP1 and total TGF-b1 in PAN and PHN
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animals at day 11 was compared to double staining for TSP1 and
latent TGF-b1 on serial sections.
In vivo disease models
Experimental mesangial proliferative nephritis was induced in
180 to 220 g male Wistar rats (Simonsen Laboratories, Gilroy,
CA, USA) by i.v. injection of goat anti-rat thymocyte plasma (0.4
cc/100 g body wt) as previously described [19]. Rats were sacri-
ficed and renal biopsies obtained at days 2, 5, 7, 10, 14, and 21
(N 5 6 to 9 per timepoint). Six normal rats (day 0) served as
controls. Experimental membranous nephropathy (PHN) [20] was
induced in male Sprague-Dawley rats (Simonsen) weighing 190 to
210 g by i.p. injection (5 ml/kg body wt) of sheep antibody to Fx1A
prepared as previously described [21]. Rats with PHN were
sacrificed at 5, 10, 15, and 21 days for renal biopsies (N 5 6 at each
time point). Aminonucleoside nephrosis (PAN) was induced in
190 to 220 g male Sprague-Dawley rats (Simonsen, Gilroy, CA) by
a single i.v. injection of puromycin as described elsewhere [22].
Rats were sacrificed at days 3, 5, 11, 14, and 21 (N 5 6 at each time
point). In a separate study, rats with PAN and PHN (N 5 5 each)
underwent survival biopsies [23] at day 11 and were sacrificed at
day 21.
Renal morphology and immunohistochemistry
Renal biopsies were fixed in methyl Carnoy’s solution and
embedded in paraffin. Indirect immunoperoxidase staining of 4
mm sections was performed as described previously [24] using the
following primary antibodies: the murine monoclonal antibody
TSP A6.1 (IgG1; kindly provided by Dr. V. Dixit; [25]), a murine
monoclonal IgM antibody against PCNA (19A2, Coulter Immu-
nology, Hialeah, FL, USA), a murine monoclonal IgG1 antibody,
ED-1, to a cytoplasmic antigen present in monocytes, macro-
phages and dendritic cells (Bioproducts for Science, Inc., India-
napolis, IN, USA), a murine monoclonal IgG2 antibody against
a-smooth muscle actin (Sigma Chemical Co., St. Louis, MO,
USA); a murine monoclonal IgG antibody, PGF-007, to a 25-
amino acid peptide of the human PDGF-B chain (Mochida
Pharmaceutical, Tokyo, Japan); a peptide affinity-purified rabbit
polyclonal antibody to TGF-b1 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); an affinity-purified polyclonal goat antibody to
recombinant human TGF-b1 latency associated peptide (rhLAP
TGF-b1; R&D Systems, Minneapolis, MN, USA; [26]), a rabbit
polyclonal antibody against rat fibronectin (Chemicon, Temecula,
CA, USA), and a rabbit polyclonal antibody against collagen IV
(Collaborative Research Inc., Bradford, MA, USA). Controls
included omitting the primary antibody and substitution of the
primary antibody with pre-immune rabbit or mouse serum. The
specificity of the monoclonal anti-TSP1 antibody, TSP A6.1, in rat
kidney has been demonstrated elsewhere [14].
For each biopsy 12 to 25 cortical fields measuring 0.25 mm2 at
a 3200 magnification using a grid in the eyepiece of the micro-
scope were evaluated in a blinded fashion. Two different methods
were used to quantitate immunostaining in the tubulointerstitium.
First, TSP1 expression was graded by counting the percentage of
positive tubules or tubules that were surrounded by interstitial
extra- or intracellular TSP1 staining. Second, a semiquantitative
scoring system (0 to 4) was developed: score 0 5 0 to 5%, score
1 5 6 to 25%, score 2 5 26 to 50%, score 3 5 51 to 75%, score
4 5 76 to 100% of tubules are positive or surrounded by positive
TSP1 staining within the grid. This semiquantitative scoring
system was compared to the above described method to count the
percentage of positive tubules during the complete timecourse of
PHN. The data from both methods were highly correlated (r 5
0.99, P , 0.001), which allowed us to evaluate the degree of
fibronectin, collagen IV, myofibroblast (a-smooth muscle actin
staining) or macrophage accumulation (ED-1 staining) in all
models using an equivalent scoring system [0–4]. Interstitial
fibrosis was scored semiquantitatively on biopsies stained with
Masson’s Trichrome using the following scoring system (0 to 3):
score 0 5 normal interstitium and tubules, score 1 5 mild fibrosis
with minimal interstitial thickening between the tubules, score 2 5
moderate fibrosis with moderate interstitial thickening between
the tubules, and score 3 5 severe fibrosis with severe interstitial
thickening between the tubules.
Immunohistochemical double staining
To determine the cell types expressing TSP1, double immuno-
staining with the TSP A6.1 antibody and cell specific markers for
interstitial cells [macrophages, ED-1 (a murine monoclonal IgG1);
myofibroblasts, a-smooth muscle actin (a murine monoclonal
IgG2A); and proliferating cells, PCNA (a murine monoclonal
IgM)] was performed using an indirect immunoperoxidase tech-
nique. Alpha-smooth muscle actin, ED-1 or PCNA antibody was
incubated overnight at 4°C, followed sequentially by biotinylated
rabbit anti-mouse IgG2A, IgG1 or IgM serum (Zymed, San
Francisco, CA, USA), peroxidase conjugated Avidin D (Vector,
Burlingame, CA, USA), color development with DAB without
nickel chloride. Incubation in 3% H2O2/methanol for 20 minutes
prevented any remaining peroxidase activity. Subsequently, the
TSP A6.1 antibody was applied overnight at 4°C, followed by
peroxidase conjugated rat anti mouse IgG1 antibody and one of
the following color reagents by choice: True blue (Kirgaard &
Perry Laboratories, Gaithersburg, MD, USA), Vector purple
(Vector), DAB with nickel. For sequential double staining with
two murine monoclonal IgG1 antibodies (TSP A6.1 and ED-1) an
additional blocking step (after the H2O2 treatment) with Fab
anti-rabbit and anti-mouse IgG was performed for one hour.
Controls included omitting either the primary antibodies or
replacing them by mouse serum, as well as omitting either the
secondary antibodies. The same protocol was used to double stain
for TSP1 and the cytokines PDGF-BB, TGF-b1 or LAP-TGF-b.
The reproducibility of this staining pattern with antibodies against
TGF-b1 and LAP-TGF-b was also confirmed in Bouin’s fixative.
In situ hybridization for thrombospondin 1 mRNA
Thrombospondin 1 mRNA was detected by in situ hybridization
on formalin-fixed tissue using 35S-labeled anti-sense probes to rat
TSP1 [14]. Sense RNA probes were used as controls. In situ
hybridization for TSP1 mRNA has been shown to correlate tightly
with the quantification of TSP1 mRNA by Northern blot analysis
of glomerular RNA in the anti-Thy1 model [14]. Hybridization
was performed using a protocol of Wilcox et al [27].
Combined immunohistochemistry and in situ hybridization
Immunoperoxidase staining for a-smooth muscle actin in com-
bination with in situ hybridization for TSP1 mRNA was per-
formed as described elsewhere [14]. In brief, the immunostaining
was done first under RNAse free conditions, followed directly by
the in situ hybridization procedure.
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Transforming growth factor-b1 bioactivity
Protein from kidney cortex was extracted using a buffer con-
taining 1% triton, 10% glycerol, 20 mM HEPES, 100 mM NaCl
with 10 mg/ml leupeptin, 10 mg/ml antipain, 10 mg/ml pepstatin,
0.1 mM sodium orthovanadate and 50 mM sodium fluoride (re-
agents purchased from Sigma) as described before [28]. The
cortical tissue was homogenized using a polytron for 30 seconds,
and placed on ice for 10 minutes, followed by centrifugation at
14000 rpm for five minutes. The protein concentration in the
supernatant was measured by BCA protein assay (Pierce, Rock-
ford, IL, USA). Transforming growth factor-b1 bioactivity was
measured by a quantitative solid phase enzyme immunoassay
according to the instructions of the manufacturer (Quantikine
TGF-b1 kit; R & D Systems, Minneapolis, MN, USA). To
determine the amount of total versus active TGF-b1 from control
(N 5 4), day 11 PAN (N 5 4), and day 11 PHN animals (N 5 5),
the protein extracted from each kidney was divided as follows: (1)
10 to 15 mg was used to measure the amount of active TGF-b1
present (no acid activation); (2) 1 mg of protein was acid activated
with 1 N HCl to determine the total amount of TGF-b1 that can
be activated. The glomerular protein extracts were added to a
microtiter plate coated with the TGF-b receptor that only allows
binding of active TGF-b, and were incubated for three hours.
After washing, a horseradish peroxidase-linked polyclonal anti-
body specific for TGF-b1 was added for two hours, followed by a
substrate solution. The optical density was measured by 450 nm.
The concentration of TGF-b1 (pg/mg protein) from the cortical
preparations was measured by comparing the optical density of
each sample to a standard curve prepared using recombinant
TGF-b1.
Statistical analysis
All values are expressed as mean 6 SD unless stated otherwise.
Statistical significance (defined as P , 0.05) was evaluated using
the Student’s t-test or one way analysis of variance with modified
t-tests using the Bonferroni method.
RESULTS
Interstitial fibrosis occurs late and to different degrees in all
three models of glomerular disease
As described previously [23], all three models of glomerular
disease (anti-Thy1, PAN, PHN) were accompanied by tubuloin-
terstitial injury with tubular dilation and atrophy, tubular cast
formation, infiltration of mononuclear cells and accumulation of
extracellular matrix. Using Masson’s Trichrome staining tech-
nique, which identifies matrix proteins (mainly collagens), areas of
interstitial fibrosis were easily detectable and semiquantitatively
scored from 0 to 3 (Table 1) as described in the Methods section.
While the onset of (detectable) interstitial fibrosis in all models
started uniformly around days 10 to 14 after disease induction and
increased progressively during disease, the degree of interstitial
fibrosis in these models varied considerably. Interstitial fibrosis
was mildest in the anti-Thy1 model, moderate in PAN, but
dramatic in PHN (Table 1).
Thrombospondin 1 protein and mRNA are up-regulated in the
tubulointerstitium in all models of glomerular disease and
precede tubulointerstitial fibrosis
In the normal rat renal cortex, TSP1 protein (Fig. 1A) and
mRNA (Fig. 1 B, C) were rarely detectable in parietal epithelial
cells of Bowman’s capsule and juxtaglomerular cells, but absent
within the tubulointerstitium. In contrast to the cortical tubuloin-
terstitium, TSP1 protein and mRNA were expressed by tubular
and collecting duct cells within the medulla (not shown).
In all three models of GN, TSP1 protein and mRNA were
expressed de novo in the cortical tubulointerstitium early in the
course of disease (Table 1 and Fig. 1). In the anti-Thy1 model,
only a mild and focal increase of TSP1 protein was observed,
starting very early on day 2, peaking on day 5 parallel to the
glomerular expression [14] and subsiding thereafter. Despite the
early onset of TSP1 expression, interstitial fibrosis was not de-
tected before day 14 in the anti-Thy1 model, when TSP1 expres-
sion was already subsiding. In PAN, TSP1 was also only focally
increased, starting early on day 5 and peaking on day 14.
Table 1. Tubulointerstitial fibrosis (Masson’s Trichrome), thrombospondin 1 expression, “myofibroblast” (a-sm actin), and macrophage (ED-1)
accumulation in anti-Thy 1 nephritis, aminonucleoside nephrosis (PAN), and passive Heymann nephritis (PHN) by immunostaining using a
semiquantitative visual scoring system or counting of the percentage of positive tubules per cross section
Parameter Model Day 0 Day 2/3 Day 5 Day 7 Day 10/11 Day 14/15 Day 21
Fibrosis Anti-Thy 1 0 6 0 0 6 0 0 6 0 0 6 0 0.1 6 0.1 0.3 6 0.1 0.5 6 0.4
Trichrome, PAN 0 6 0 0 6 0 0 6 0 ND 0.1 6 0.1 0.4 6 0.1 0.9 6 0.3
score 0–3 PHN 0 6 0 ND 0 6 0 ND 0.4 6 0.1 0.4 6 0.4 2.0 6 0.7
TSP1 Anti-Thy 1 0 6 0 1.4 6 0.4 3.6 6 0.7 2.8 6 0.8 1.0 6 0.3 1.0 6 0.4 0 6 0
% tubules PAN 0 6 0 ND 1.1 6 1.1 ND 1.8 6 1.0 7.0 6 2.6 2.2 6 0.3
positive PHN 0 6 0 ND 5.6 6 2.7 ND 26.3 6 2.2 8.8 6 6.4 3.6 6 0.1
Myofibroblasts Anti-Thy 1 0 6 0 0.6 6 0.1 0.8 6 0.2 0.9 6 0.2 0.9 6 0.3 1.0 6 0.3 0.7 6 0.1
a-sm-actin, PAN 0 6 0 ND 0.5 6 0.2 ND 2.7 6 0.1 1.8 6 0.3 1.1 6 0.1
score 0–4 PHN 0 6 0 ND 0.9 6 0.1 ND 2.6 6 0.3 1.7 6 0.7 1.5 6 0.4
Macrophages Anti-Thy 1 0 6 0 ND 0.6 6 0.1 0.8 6 0.2 0.9 6 0.3 0.8 6 0.3 0.4 6 0.1
ED-1, PAN 0 6 0 ND 0.9 6 0.1 ND 2.2 6 0.2 2.7 6 0.4 1.3 6 0.2
score 0–4 PHN 0 6 0 ND 0.1 6 0.1 ND 0.8 6 0.3 1.2 6 0.7 1.8 6 0.4
All the data at the peak in regard to fibrosis, TSP1 expression, myofibroblast-, and macrophage accumulation are significant (P , 0.01). Data are mean
SD. Abbreviations are: ND, not done; a-sm actin, a smooth muscle actin.
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Detectable interstitial fibrosis started on day 14 and peaked on
day 21. Thrombospondin 1 was also induced in the tubulointer-
stitium of the PHN model, where its expression started on day 5,
peaked on day 10 and declined later in disease. Again, interstitial
fibrosis developed after the onset of TSP1 expression, being
minimally elevated at the peak of TSP 1 expression on day 10, but
substantially elevated later on in disease (Table 1).
Thrombospondin 1 protein expression was paralleled by tubu-
lointerstitial TSP1 mRNA expression in all three models (as
assessed by in situ hybridization; Fig. 1) and followed a specific
pattern. The early expression of TSP1 (day 5) was commonly
confined to proximal and distal tubular cells after injury (Fig. 1D,
E, F). At later time points (day 10), TSP1 was still predominantly
expressed by tubular cells, but was also present in the extracellular
space in the interstitium and in a heterogenous cell population of
round and spindle shaped interstitial cells (Fig. 1 G, H, I).
Identification of the cells expressing thrombospondin 1 protein
and mRNA
Most of the TSP1 protein and TSP1 mRNA is produced by
injured/dilated proximal and distal tubular cells in the typical
sequence during all three disease models as described above. In
order to characterize the fewer cells expressing TSP1 in the
interstitium, we performed double immunolabeling for TSP1
(TSP A6.1) and proliferating cells (PCNA), macrophages (ED-1),
or activated interstitial (myo-) fibroblasts (a-smooth muscle ac-
tin). Double immunostaining of TSP A6.1 with PCNA, ED-1 or
a-smooth muscle actin antibody in these disease models showed
that, although some TSP1 expressing interstitial cells were also
proliferating and/or ED-1 positive macrophages, the majority of
TSP1 positive interstitial cells were a-smooth muscle actin posi-
tive myofibroblasts (Fig. 2A; PHN day 10). This cellular expres-
sion pattern was confirmed by combining in situ hybridization of
TSP1 mRNA with immunostaining for a-smooth muscle actin,
which showed localization of TSP1 mRNA in a-smooth muscle
actin positive myofibroblasts (Fig. 2B; PHN day 10) besides the
predominant tubular expression.
Thrombospondin 1 expression differs from that of other
extracellular matrix proteins
To determine whether the time course of TSP1 expression is
similar to or different from other extracellular matrix proteins, the
kinetics of collagen IV and fibronectin were compared to TSP1 in
all models. While tubulointerstitial TSP1 was induced early and
only transiently in these disease models, interstitial staining for
collagen IV and fibronectin increased later and paralleled closely
the timecourse of interstitial fibrosis as assessed by the Trichrome
staining. Figure 3 shows the typical time course of TSP1 compared
to collagen IV and fibronectin expression in the PHN model.
Interstitial macrophages and “myofibroblasts” predict
interstitial fibrosis less well than thrombospondin 1 expression
In all models examined the development of tubulointerstitial
fibrosis was preceded by the appearance of ED-1 positive macro-
phages (Table 1) and a-smooth muscle actin positive myofibro-
blasts (Table 1) within the tubulointerstitium, similar to the
increase in TSP1 expression. However, while the degree of early
TSP1 expression correlated closely with the extent of interstitial
fibrosis later in all models, neither the degree of early macrophage
nor of early myofibroblast accumulation in the interstitium corre-
lated with the severity of interstitial fibrosis in these glomerulo-
nephritis models (Table 2). While the number of infiltrating
macrophages in the early phase was greatest in PAN, interstitial
fibrosis and TSP1 expression in this model was only moderate. In
the PHN model, which is characterized by more severe interstitial
fibrosis and TSP1 expression, the interstitial infiltrate of macro-
phages was less than in the PAN model for all time points except
day 21. Similarly, the degree of myofibroblast accumulation did
not differ in the PAN or PHN model despite significant differ-
ences in the degree of interstitial fibrosis. Only on day 21, when
tubulointerstitial fibrosis was already established, macrophage
and myofibroblast accumulation correlated well with the degree of
fibrosis (Table 2).
In contrast, the peak TSP1 expression occurring early in disease
correlated closely with the maximal interstitial fibrosis occurring
at day 21 in these disease models (anti-Thy1 model , PAN ,
PHN; Table 1). To examine this directly, expression of TSP1 on
day 11 in PHN and PAN animals (survival biopsies) was corre-
lated with the degree of interstitial fibrosis on day 21 in the same
animals (sacrificial biopsies). Figure 4 demonstrates that the TSP1
expression on day 11 in these individual animals correlated tightly
with the degree of interstitial fibrosis on day 21 (r 5 0.95, P ,
0.0001). In addition, animals that showed a more pronounced
TSP1 expression in areas of the juxtamedullary tubulointerstitium
on day 11 also demonstrated a predominant juxtamedullary
pattern of interstitial fibrosis on day 21. Animals with diffuse
tubulointerstitial TSP1 expression on day 11 showed diffuse
distribution of fibrosis later.
Thrombospondin 1 expression colocalizes with TGF-b1 in
tubulointerstitial disease, but not with PDGF-BB expression
Interstitial PDGF-BB expression in all disease models exam-
ined did not show major changes compared to normal controls.
Tubular PDGF-BB expression was focally increased during the
time course of these glomerulonephritis models. However, double
labeling of TSP1 with PDGF-BB did not show coexpression (not
shown).
However, both TSP1 and TGF-b1 were increased and coex-
pressed in areas of tubulointerstitial injury. Transforming growth
factor-b1 in the normal kidney is hardly expressed in glomerulus
(possibly at low levels in glomerular epithelial cells), but is
abundant in proximal and distal tubular cells. This expression
pattern could also be found by staining with an antibody against
LAP-TGF-b, suggesting that most of the TGF-b1 is in its latent
form. In disease, while TSP1 and total TGF-b1 were increased in
tubular and interstitial cells in areas of tubulointerstitial injury,
LAP-TGF-b was predominantly decreased in these areas. We
performed double staining for TSP1 and TGF-b1 (Fig. 5A) as well
as for TSP1 and LAP-TGF-b1 (Fig. 5B) on serial sections.
Comparing these consecutive sections, we could identify areas of
injury in which increased TSP1 expression was associated with
increased total TGF-b1 expression (Fig. 5A), but not with a
comparable increase or frequently even a decrease in LAP-TGF-b
(Fig. 5B), suggesting a net increase in the active fraction of
TGF-b1 (without LAP) in these areas of de novo expression of
TSP1. Interestingly, the glomerular expression of TGF-b also
increased concomittently with TSP1 in experimental mesangial
proliferative nephritis (anti-Thy 1 model). In contrast, no increase
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of either TSP1 or TGF-b1 were noted in glomeruli in the PHN
and PAN models, consistent with prior studies [28].
Interstitial thrombospondin 1 expression is associated with
TGF-b1 expression and bioactivity in PAN and PHN
Using an enzyme immunoassay, we determined the amount of
active and total TGF-b1 in cortical tissue samples from rats with
PAN and PHN at day 11. Since immunostaining for TGF-b1 did
not show any significant increases in TGF-b1 within the glomer-
ulus at this time point, differences in TGF-b1 bioactivity from
cortical samples of diseased animals were considered to reflect
changes in the tubulointerstitium. The measurement of the active
fraction of TGF-b1 (without acid activation, 0.5 6 0.1 pg TGF-
b1/mg protein) in normal cortical tissue showed that only about
Fig. 1. Thrombospondin 1 (TSP1) protein and mRNA are expressed de novo in areas of tubulointerstitial injury accompanying glomerular disease. In
normal rats, TSP1 protein (dark immunostaining, A) and mRNA (in situ hybridization, B) darkfield showing positive signal by white grains, (C)
brightfield showing positive signal by dark grains] were expressed occasionally by parietal glomerular epithelial cells (arrow), but were absent in the
tubulointerstitium. The early expression of TSP1 protein (D) and mRNA [(E) darkfield, (F) brightfield] was commonly confined to proximal and distal
tubular cells after injury and was mainly intracellular in location (here PHN day 5).
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1% of total TGF-b1 (after acid activation, 50.0 6 2.5 pg TGF-
b1/mg protein) is active. This result is consistent with a widely
overlapping distribution of TGF-b1 and LAP-TGF-b (see immu-
nostaining above). In diseased animals at day 11, the active
TGF-b1 fraction (no acid activation) increased significantly (P ,
0.05) up to three times (PAN day 11, 1.5 6 0.3 pg TGF-b1/mg
protein; PHN day 11, 1.5 6 0.5 pg TGF-b1/mg protein) versus
normal controls. The total TGF-b1 bioactivity (after acid activa-
tion) also increased significantly (P , 0.05) up to two times in
diseased animals versus normal controls (PAN day 11, 101.9 6
21.1 pg TGF-b1/mg protein; PHN day 11, 89.0 6 36.3 pg
TGF-b1/mg protein). Comparison of the degree of tubulointer-
stitial TSP1 expression with the amount of TGF-b1 bioactivity
(both active and total) in individual animals at day 11 in PAN,
PHN, or controls revealed a high correlation (r 5 0.93/0.94, P ,
0.001; Fig. 6 A, B).
DISCUSSION
Tubulointerstitial fibrosis is a major determinant for both renal
function and prognosis in glomerular disease [1–4, 29]. Throm-
bospondin 1 is an extracellular matrix protein that has been shown
to have a role in PDGF- and bFGF-mediated proliferation in
various cell types, and to also be an endogenous activator of
TGF-b [14–16]. To study the role of TSP1 in the development of
tubulointerstitial fibrosis, we compared several models of glomer-
ulonephritis (anti-Thy1 model, PAN, and PHN) characterized by
Fig. 1. Cont’d. At later time points, TSP1 protein (G) and mRNA
[(H) darkfield, (I) brightfield] were identified in the extracellular space
in the interstitium and also were present in a heterogenous cell
population of round and spindle shaped interstitial cells (here PHN day
10).
Hugo et al: Thrombospondin 1 is a marker for early TIN 307
tubulointerstitial disease with tubular atrophy and dilation, mono-
nuclear cell infiltrate, myofibroblast formation, and matrix expan-
sion. Thrombospondin 1 mRNA and protein expression were
transiently expressed (de novo) in areas of tubulointerstitial injury;
TSP1 expression localized preferentially to tubular cells, and to a
lesser degree to inflammatory interstitial myofibroblasts and
macrophages, and correlated quantitatively and spatially with the
later development of tubulointerstitial fibrosis.
In all disease models studied, TSP1 mRNA and protein were de
novo and transiently expressed in areas of tubulointerstitial injury,
starting as early as day 2 in anti-Thy1 disease and day 5 in PAN,
and PHN, peaking between day 5 (anti-Thy1 disease) and day
10/11 (PHN/PAN), and subsiding afterwards. Thrombospondin 1
(mRNA and protein) expression was initially intracellular and
limited (mainly) to tubular cells and later was present in extracel-
lular areas in the interstitium. Later in disease TSP1 expression
was also localized to a lesser degree to myofibroblasts and
macrophages (shown by double staining for TSP1 and cell specific
markers), but still seems to be predominantly produced by injured
tubular cells. The early and transient tubulointerstitial expression
of TSP1 is unique and different from other common extracellular
matrix proteins such as fibronectin and collagen IV. These latter
extracellular proteins paralleled the development of interstitial
fibrosis suggesting that they are more permanently incorporated
in the interstitial matrix and participate structurally in the process
of interstitial fibrosis, in contrast to TSP1.
A major finding was that early tubulointerstitial TSP1 expres-
sion correlated with both the development and degree of tubulo-
interstitial fibrosis in all three disease models (Table 2). This was
further supported by studies in individual animals with PAN or
PHN in which both the site and degree of TSP1 expression at day
11 correlated with site and degree of tubulointerstitial fibrosis at
day 21. Thrombospondin 1 expression was superior to the degree
of early macrophage or myofibroblast accumulation in predicting
the later development of fibrosis. These data do not question that
macrophages or myofibroblasts are involved in the development
of tubulointerstitial fibrosis, as previous studies suggest [7–9, 12,
30–32], but suggest that other factors such as local expression of
TSP1 and possibly other cytokines, may have an important
influence on the fibrotic process.
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Fig. 3. Thrombospondin (TSP1) expression
precedes the accumulation of other
extracellular matrix proteins. This graph
illustrates the kinetics of tubulointerstitial
collagen IV (L) and fibronectin (M) expression
in comparison to TSP1 (E) in the PHN model
(similar in other models examined). While
tubulointerstitial TSP1 was induced early and
only transiently in PHN, collagen IV and
fibronectin were increased later and paralleled
closely the time course of interstitial fibrosis (;
see Table 1).
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Fig. 4. Tubulointerstitial thrombospondin (TSP1) expression predicts
the development of interstitial fibrosis. Expression of TSP1 (immuno-
staining, score 0 to 4) on day 11 in control, PHN and PAN animals
(survival biopsies) was correlated with the degree of interstitial fibrosis
(Trichrome staining, score 0 to 3) on day 21 in the same animals (sacrifical
biopsies). TSP1 expression correlated tightly with the degree of interstitial
fibrosis (r 5 0.95, P , 0.0001) in these individual animals.
Table 2. Regression analysis (r-value) of TSP 1 expression,
myofibroblast (a-sm actin), or macrophage (ED-1) accumulation on
days 10/11, 14/15 or 21 in anti-Thy 1 disease, PAN, and PHN for the
prediction of tubulointerstitial fibrosis (Trichrome) on day 21
Analysis Day 10/11 Day 14/15 Day 21
TSP1/fibrosis 0.98 0.83 0.92
Myofibroblast/
fibrosis
0.65 0.55 0.96
Macrophages/
fibrosis
0.34 0.1 0.89
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The temporal and spatial relationship of TSP1 expression to the
tubulointerstitial fibrosis suggests a functional/causal relationship.
Thrombospondin 1 has been implicated in proliferation in several
cultured cell types (fibroblasts, mesangial, endothelial, and vascu-
lar smooth muscle cells), either via stimulation of PDGF or
independently [13, 33, 34]. While the time course of tubulointer-
stitial proliferation (peaking at day 10 in PHN) was very similar to
the transient expression of TSP1, double staining of TSP1 with
PCNA (a marker of proliferation) did not show colocalization
(not shown). Within the tubulointerstitium, PDGF was only
mildly up-regulated in certain tubular areas of injury, but not in
interstitial cells and did not colocalize with TSP1 expression.
Thrombospondin 1 has also been shown to stimulate the
expression of a-smooth muscle actin by fibroblasts in a model of
aortic explants [35] and to mediate monocyte diapedesis in vitro
[36]. Although macrophages and myofibroblasts are coexpressed
with TSP1 in areas of tubulointerstitial injury, the correlation of
TSP1 expression with these cell types was not strong, suggesting
that TSP1 does not have a major role in the accumulation of these
cell types at the sites of injury.
The fibrosis-promoting effects of TGF-b have been well estab-
lished in vitro and in vivo in diseases of the kidney and several
other organs [37]. Transforming growth factor-b is considered to
be a major cytokine linking tissue injury to scarring, not only in the
glomerulus [18, 38], but also within the tubulointerstitium, includ-
ing in the PAN [39] and PHN [40] models. Transforming growth
factor-b is secreted in a biologically inactive or latent form that
consists of a mature, biologically active component noncovalently
associated with the TGF-b latency associated peptide (LAP-
TGF-b) and variably with a latent TGF-b binding protein (LTBP)
Fig. 2. Alpha-smooth muscle actin positive myofibroblasts are a source
of interstitial thrombospondin 1 (TSP1) protein (a) and mRNA (b)
expression during the development of fibrosis. While TSP1 is predomi-
nantly expressed in tubular cells during TI-injury, double immunostaining
for a-smooth muscle actin (brown) and TSP1 (blue grains) identified that
some a-smooth muscle actin positive interstitial cells were also positive for
TSP1 (arrows in a, here PHN day 10). Combination of in situ hybridization
for TSP1 mRNA (dark grains) and immunostaining for a-smooth muscle
actin (brown) confirmed expression of TSP1 mRNA by interstitial myofi-
broblasts (arrows in b, here PHN day 10). Tubular expression of TSP1
protein (a, blue grains) and TSP1 mRNA (b, black grains) during disease
can also be appreciated.
Fig. 5. De novo expression of thrombospondin (TSP1) co-localizes to sites
of increased transforming growth factor beta1 (TGF-b1) and decreased
latency associated peptide of TGF-b (LAP-TGF-b) expression during
tubulointerstitial injury. These photographs reveal double immunostain-
ing for TSP1 (blue color in a and b) and TGF-b1 (brown color in a) as well
as TSP1 and LAP-TGF-b1 (brown color in b) on serial sections (A/B). In
disease (here PAN day 11), while TSP1 TGF-b1 were increased and
coexpressed in tubular and interstitial cells in areas of tubulointerstitial
injury (arrow in a), LAP-TGF-b1 was decreased in the same area of the
consecutive section (arrow in b). The equal staining intensity of TGF-b1
(a) and LAP-TGF-b1 (b) of TSP1 negative, nondilated (and presumably
uninjured) tubules can be noted (arrowheads).
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[41–43]. Despite great interest and possible therapeutic relevance,
the endogenous factor(s) mediating the activation of this TGF-b
complex during in vivo disease processes are still unknown.
Recently, TSP1 has been shown to bind and activate TGF-b in
vitro [16, 17]. Activation of latent TGF-b by TSP1 is mediated by
two sequences present in the type 1 repeats of TSP1 [44] a
sequence that binds to TGF-b and may orient the TSP1 molecule
and a second sequence that activates latent TGF-b [45]. This
study does not prove, but is consistent with the hypothesis that
TSP1 may be an endogenous activator of latent TGF-b. First, the
de novo expression of TSP1 frequently colocalized with increased
TGF-b1 in areas of tubulointerstitial injury. Second, cortical
TGF-b1 bioactivity measurements (total and active) at the peak of
TSP1 expression at day 11 in PAN and PHN were also increased
up to two- to threefold and highly correlated with the degree of
tubulointerstitial TSP1 expression in the same animals (Fig. 6 A
and B). It is interesting to note that even in diseased animals the
great majority of TGF-b1 is in its latent form, unlike in vitro
experiments where up to 60% of the latent TGF-b can be
activated by TSP1 for example [17]. In this regard it has to be
considered that measurements of TGF-b1 activity in whole corti-
cal tissue, where large areas of the tubulointerstitium are unaf-
fected, do not necessarily reflect the focal areas where TGF-b1 is
being activated. Third, TSP1 positive areas of tubulointerstitial
injury were frequently accompanied by an increase in total
TGF-b1, but a decrease in LAP-TGF-b1. The observation of de
novo expression of TSP1 with expression of TGF-b1 and de-
creased expression of LAP-TGF-b suggests that TSP1 may be
involved in the local activation of TGF-b.
In conclusion, de novo expression of TSP1 in the tubulointer-
stitium of several experimental glomerulonephritis models pre-
ceded and highly predicted the development of interstitial fibrosis.
Thrombospondin 1 expression was associated with TGF-b1 ex-
pression and decreased LAP-TGF-b expression in areas of tubu-
lointerstitial injury. Future studies with specific peptides blocking
TGF-b1 activation by TSP1 may prove the attractive hypothesis
that TSP1 is an endogenous activator of TGF-b1 and an impor-
tant mediator of interstitial fibrosis.
ACKNOWLEDGMENTS
The authors are grateful to Dr. V. Dixit (University of Michigan, Ann
Arbor, MI) for providing the murine monoclonal anti-thrombospondin
antibody A6.1. This work was supported in part by United States Public
Health Service grants (DK-43422, DK-02142, DK34198, DK51096,
DK52121, and HL 18645) and by an NIH George O’Brien Kidney Center
grant (DK47659), and by a post-doctoral stipend of the Deutsche For-
schungsgemeinschaft as well as the National Kidney Foundation to C.H.
Portions of this work were presented at the American Society of Nephrol-
ogy annual meeting, San Diego, CA, October 26–29, 1995 and published
in abstract form (J Am Soc Nephrol 5:782, 1994).
Reprint requests to Christian Hugo, M.D., Division of Nephrology, Box 356
521, BB-1265 Health Sciences, University of Washington Medical Center,
Seattle, Washington 98195, USA.
APPENDIX
Abbreviations used in this paper are: bFGF, basic fibroblast growth
factor; DAB, diaminobenzidine; GN, glomerulonephritis; LAP, latency
associated peptide; MC, mesangial cell; PAN, puromycin aminonucleoside
nephrosis; PCNA, proliferating cell nuclear antigen; PHN, Passive Hey-
mann nephritis; PDGF, platelet-derived growth factor; TGF-b, transform-
ing growth factor-b; TSP1, thrombospondin 1.
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